Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review

Executive Summary

FDA clinical reviewers moved from traditional “new drug” review mode to determining the evidence needed to demonstrate a follow-on product is highly similar to the reference biologic, Sandoz exec says, describing firm’s interactions with FDA on its filgrastim 351(k) application.

Advertisement

Related Content

Sandoz Makes First Biosimilar Review Look Easy; Will Future Sponsors Be As Lucky?
EU Data Helps Sandoz’s U.S. Clinical Program For Filgrastim
Apotex Biosimilar Goes To FDA, But May Enter Crowded Market
Apotex Biosimilar Goes To FDA, But May Enter Crowded Market
Sandoz Neupogen Biosimilar Heads To ODAC; Cmte. May Be Students As Much As Advisors
Biosimilar Guidances Expected In ‘Near Future,’ But Unnecessary, FDA Says
Biosimilar Guidances Expected In ‘Near Future,’ But Unnecessary, FDA Says
Biosimilars in 2014: An Interview With FDA New Drugs Head John Jenkins
Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway
Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel